10h
Loose Women panellist Nadia Sawalha has been campaigning for the life-changing drug Enhertu to be made available in Wales, ...
Zacks.com on MSN7d
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded UseAstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...
Enhertu improved the time it took for patients with a breast cancer subset to experience worsening pain and other symptoms, ...
The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...
Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer: Tokyo Saturday, October 5, 2024, 10:00 Hrs [IST] Daiich ...
The companies said Enhertu is the first HER2-directed therapy to show a strong tumour response in this population, which accounts for 2% to 4% of all NSCLC cases. Image Phil Taylor ...
Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective ...
At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback